CS MEDICA Expands Presence in Eastern Europe through New Partnership

REG

CS MEDICA announces that its subsidiary, CANNORDIC, has established a white-label partnership with Deutsch-Pharm, a top pharmaceutical distributor in Ukraine. This deal is subject to successful product registration with Ukrainian health authorities and includes a 100% prepayment from Deutsch-Pharm upon registration approval, expected within a 1–2-month timeframe. The selected skin duo, comprising the Psoriasis Gel and Skin Relief Lotion, offers a comprehensive treatment solution. The gel is already compliant with the EU's Medical Device Regulation (MDR), ensuring safety and effectiveness, while the cosmetic regulated skin lotion perfectly complements the treatment.

CS MEDICA prefers not to work with exclusivity; however, the grant of exclusive distribution rights to Deutsch-Pharm reflects CS MEDICA's strategy to support its Ukrainian partner and maximize market entry.

Lone Henriksen, CEO of CS MEDICA, states, "Deutsch-Pharm visited us at CPHI in October, and we are pleased to have an agreement in place where we can enhance our footprint in the Eastern Europe market and especially demonstrate our commitment to supporting our customer as consumers under challenging conditions. While we have a three-year forecast in place, our immediate focus is on the swift launch of the first 20,000 units, utilizing the strength of our MDR-compliant skincare solution to expedite local registration and product availability"

Huzar Pavlo, General Manager for Deutsch-Pharm, comments: “We are happy for the exclusivity granted, which underscores the support and confidence CANNORDIC has in our operations during these challenging times. With Deutsch-Pharm's robust distribution network and our commitment to delivering MDR-compliant products, we are poised to make an impact on the healthcare market. These unique products will allow us to effectively meet the growing demand for advanced skincare solutions and ensure that these innovative treatments are accessible to all Ukrainians.”

Deutsch-Pharm maintains a robust distribution network, with facilities in Kyiv, Dnipro, and Lviv, ensuring a localized market penetration and accessibility of CANNORDIC's products throughout Ukraine.
 

Datum 2024-11-11, kl 08:00
Källa Cision
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!